![]() ![]() Many LAMA/LABA fixed dose combinations have been licensed in different countries and the clinical use of these drugs stimulated the performance of many clinical trials. Currently the Global initiative for COPD suggests the use of long acting beta agonists (LABAs) and long acting muscarinic antagonists (LAMAs) in combination for the majority of COPD patients, thus great interest is associated with the developing of LAMA/LABA fixed combination in the maintenance treatment of stable COPD. The cornerstones of treatment are bronchodilator drugs of two different classes: beta agonists and muscarinic antagonists. Great efforts were spent in the development of drugs able to improve symptoms, quality of life, reduce exacerbations, hospitalizations and the frequency of death of patients with COPD. 5Department of Emergency, Spedali Civili di Brescia, Brescia, ItalyĬhronic obstructive pulmonary disease (COPD) is a common disabling disease characterized by progressive airflow obstruction.4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, Italy.3Department of Medicine, Spedali Civili di Brescia, Brescia, Italy.2Respiratory Unit, Sant’Andrea Hospital, Vercelli, Italy. ![]() 1Respiratory Medicine, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, Italy.Mario Malerba 1,2* Valentina Foci 1,2 Filippo Patrucco 1,2 Patrizia Pochetti 1,2 Matteo Nardin 3 Corrado Pelaia 4 Alessandro Radaeli 5 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |